Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory n
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above under Item 1.
Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Convertible Promissory Note, dated January 15, 2026, made by the Company in favor